JP4409845B2 - 癌診断パネル - Google Patents
癌診断パネル Download PDFInfo
- Publication number
- JP4409845B2 JP4409845B2 JP2003096170A JP2003096170A JP4409845B2 JP 4409845 B2 JP4409845 B2 JP 4409845B2 JP 2003096170 A JP2003096170 A JP 2003096170A JP 2003096170 A JP2003096170 A JP 2003096170A JP 4409845 B2 JP4409845 B2 JP 4409845B2
- Authority
- JP
- Japan
- Prior art keywords
- portfolio
- genes
- gene
- gene expression
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 6
- 201000011510 cancer Diseases 0.000 title claims description 4
- 238000003745 diagnosis Methods 0.000 title claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 90
- 230000014509 gene expression Effects 0.000 claims description 53
- 238000002493 microarray Methods 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 44
- 239000000523 sample Substances 0.000 description 20
- 238000005259 measurement Methods 0.000 description 15
- 239000003550 marker Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000010837 poor prognosis Methods 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 238000012340 reverse transcriptase PCR Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 101150094765 70 gene Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150106899 28 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36866702P | 2002-03-29 | 2002-03-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009049600A Division JP2009118855A (ja) | 2002-03-29 | 2009-03-03 | 癌診断パネル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004033215A JP2004033215A (ja) | 2004-02-05 |
| JP2004033215A5 JP2004033215A5 (https=) | 2006-03-23 |
| JP4409845B2 true JP4409845B2 (ja) | 2010-02-03 |
Family
ID=28675523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003096170A Expired - Fee Related JP4409845B2 (ja) | 2002-03-29 | 2003-03-31 | 癌診断パネル |
| JP2009049600A Pending JP2009118855A (ja) | 2002-03-29 | 2009-03-03 | 癌診断パネル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009049600A Pending JP2009118855A (ja) | 2002-03-29 | 2009-03-03 | 癌診断パネル |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7348142B2 (https=) |
| EP (1) | EP1355150A3 (https=) |
| JP (2) | JP4409845B2 (https=) |
| KR (1) | KR20030078799A (https=) |
| CN (2) | CN100577813C (https=) |
| AR (1) | AR039210A1 (https=) |
| AU (1) | AU2003203553A1 (https=) |
| BR (1) | BR0303011A (https=) |
| CA (1) | CA2422319A1 (https=) |
| MX (1) | MXPA03002862A (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1151142A2 (en) * | 1999-01-28 | 2001-11-07 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
| US7348142B2 (en) * | 2002-03-29 | 2008-03-25 | Veridex, Lcc | Cancer diagnostic panel |
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| CA2475769C (en) * | 2003-08-28 | 2018-12-11 | Veridex, Llc | Colorectal cancer prognostics |
| WO2005054508A2 (en) * | 2003-12-01 | 2005-06-16 | Ipsogen | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| WO2007017770A1 (en) * | 2005-08-05 | 2007-02-15 | Koninklijke Philips Electronics, N.V. | Search space coverage with dynamic gene distribution |
| EP2402758B1 (en) * | 2005-09-19 | 2014-09-10 | Janssen Diagnostics, LLC | Methods and uses for identifying the origin of a carcinoma of unknown primary origin |
| US20070130694A1 (en) * | 2005-12-12 | 2007-06-14 | Michaels Emily W | Textile surface modification composition |
| WO2007081385A2 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| CA2644586A1 (en) * | 2006-03-03 | 2008-04-17 | Veridex Llc | Molecular assay to predict recurrence of duke's b colon cancer |
| EP2530167A1 (en) | 2006-05-11 | 2012-12-05 | Raindance Technologies, Inc. | Microfluidic Devices |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| EP2077912B1 (en) | 2006-08-07 | 2019-03-27 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
| WO2008073578A2 (en) | 2006-12-08 | 2008-06-19 | Iowa State University Research Foundation, Inc. | Plant genes involved in nitrate uptake and metabolism |
| WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| EP4047367A1 (en) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Method for detecting target analytes with droplet libraries |
| US9512196B2 (en) | 2008-09-22 | 2016-12-06 | Cedars-Sinai Medical Center | Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling |
| EP2328911A4 (en) | 2008-09-22 | 2012-03-14 | Cedars Sinai Medical Center | SHORT HUMAN MD-2 AS A NEGATIVE REGULATOR OF GREAT LIKE RECEPTOR 4 SIGNALING |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
| US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| EP4484577A3 (en) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| CN105886657B (zh) * | 2010-09-13 | 2019-11-01 | 临床基因组学股份有限公司 | 结直肠癌的外遗传标记以及使用它们的诊断方法 |
| US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| EP3412778A1 (en) | 2011-02-11 | 2018-12-12 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
| EP3216872B1 (en) | 2011-06-02 | 2020-04-01 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
| EP2844768B1 (en) | 2012-04-30 | 2019-03-13 | Raindance Technologies, Inc. | Digital analyte analysis |
| WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
| US20160116474A1 (en) * | 2013-06-20 | 2016-04-28 | The Broad Institute, Inc. | Compositions and methods for detecting and treating glioblastoma |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| WO2015103367A1 (en) | 2013-12-31 | 2015-07-09 | Raindance Technologies, Inc. | System and method for detection of rna species |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| CN106086220A (zh) * | 2016-08-19 | 2016-11-09 | 浙江省中医院 | 一种非小细胞肺癌单核苷酸多态性检测试剂盒及其应用 |
| US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
| US12018333B2 (en) | 2018-01-23 | 2024-06-25 | Excellen Medical | Method and kit for identifying lung cancer status |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US6350576B1 (en) * | 1994-12-20 | 2002-02-26 | Cold Spring Harbor Laboratory | Cancer detection probes |
| US5695937A (en) * | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US6275814B1 (en) * | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) * | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| AU3755300A (en) | 1999-03-15 | 2000-10-04 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| US6175824B1 (en) * | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
| IL147657A0 (en) * | 1999-07-15 | 2002-08-14 | Res Dev Foundation | Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
| EP1339872A2 (en) * | 2000-09-19 | 2003-09-03 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| US7094536B2 (en) * | 2001-03-09 | 2006-08-22 | Nugen Technologies, Inc. | Methods and compositions for amplification of RNA sequences |
| WO2002101357A2 (en) * | 2001-06-10 | 2002-12-19 | Irm Llc | Molecular signatures of commonly fatal carcinomas |
| US7348142B2 (en) * | 2002-03-29 | 2008-03-25 | Veridex, Lcc | Cancer diagnostic panel |
-
2003
- 2003-03-21 US US10/393,567 patent/US7348142B2/en not_active Expired - Fee Related
- 2003-03-28 CA CA002422319A patent/CA2422319A1/en not_active Abandoned
- 2003-03-28 AU AU2003203553A patent/AU2003203553A1/en not_active Abandoned
- 2003-03-28 BR BR0303011-3A patent/BR0303011A/pt not_active Application Discontinuation
- 2003-03-29 CN CN03131207A patent/CN100577813C/zh not_active Expired - Fee Related
- 2003-03-29 KR KR10-2003-0019811A patent/KR20030078799A/ko not_active Withdrawn
- 2003-03-29 CN CN200910224989A patent/CN101705291A/zh active Pending
- 2003-03-31 EP EP03252023A patent/EP1355150A3/en not_active Withdrawn
- 2003-03-31 JP JP2003096170A patent/JP4409845B2/ja not_active Expired - Fee Related
- 2003-03-31 MX MXPA03002862A patent/MXPA03002862A/es active IP Right Grant
- 2003-04-01 AR ARP030101131A patent/AR039210A1/es not_active Application Discontinuation
-
2008
- 2008-01-29 US US12/021,439 patent/US20090221445A1/en not_active Abandoned
-
2009
- 2009-03-03 JP JP2009049600A patent/JP2009118855A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030078799A (ko) | 2003-10-08 |
| JP2009118855A (ja) | 2009-06-04 |
| US7348142B2 (en) | 2008-03-25 |
| JP2004033215A (ja) | 2004-02-05 |
| US20030194733A1 (en) | 2003-10-16 |
| CN1495275A (zh) | 2004-05-12 |
| CN100577813C (zh) | 2010-01-06 |
| US20090221445A1 (en) | 2009-09-03 |
| AU2003203553A1 (en) | 2003-10-23 |
| BR0303011A (pt) | 2004-02-17 |
| CN101705291A (zh) | 2010-05-12 |
| EP1355150A2 (en) | 2003-10-22 |
| AR039210A1 (es) | 2005-02-09 |
| EP1355150A3 (en) | 2004-08-25 |
| CA2422319A1 (en) | 2003-09-29 |
| MXPA03002862A (es) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4409845B2 (ja) | 癌診断パネル | |
| JP2004163388A (ja) | マーカーの選択 | |
| EP2852689B1 (en) | Nano46 genes and methods to predict breast cancer outcome | |
| JP4913331B2 (ja) | 結腸直腸癌の予後 | |
| CN101356532B (zh) | 基于基因的算法型癌症预后 | |
| US8183353B2 (en) | Breast cancer prognostics | |
| JP2004537261A (ja) | 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング | |
| JP2007049991A (ja) | 乳癌の骨への再発の予測 | |
| WO2006127537A2 (en) | Thyroid fine needle aspiration molecular assay | |
| JP2009153521A (ja) | 結腸直腸癌の評価 | |
| JP2009153522A (ja) | 結腸直腸癌の評価 | |
| JP2007528218A (ja) | 乳癌の予後診断 | |
| JP2007508812A (ja) | 乳癌分類に関する材料および方法 | |
| CA2912445A1 (en) | Methods to predict risk of recurrence in node-positive early breast cancer | |
| EP1367138B1 (en) | Markers for breast cancer prognosis | |
| JP2007508008A (ja) | 乳癌診断に関する物質および方法 | |
| US20170183738A1 (en) | Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers | |
| JP4886976B2 (ja) | 結腸直腸のガンの予後予測 | |
| CN118222713A (zh) | 生物标志物在检测脑胶质瘤相关tls中的应用 | |
| WO2010143941A1 (en) | Classification and risk-assignment of childhood acute myeloid leukaemia (aml) by gene expression signatures | |
| WO2009151314A1 (en) | Classification and risk-assignment of childhood acute lymphoblastic leukaemia (all) by gene expression signatures | |
| EP1679382A2 (en) | Panel of nucleic acid sequences for cancer diagnosis | |
| Best | Tumor-educated platelets: From RNA to diagnosis | |
| Byers et al. | Molecular diagnostics in haematopathology | |
| JP6757560B2 (ja) | 大腸癌の再発リスク診断を補助する方法、プログラムおよびコンピュータシステム |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060124 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090106 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090303 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090324 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090624 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090629 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091013 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091112 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121120 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |